Innovative Cancer Detection Adela's proprietary genome-wide methylation technology enables early detection, diagnosis, and management of various cancers, presenting opportunities to collaborate with healthcare providers and diagnostic labs seeking advanced, non-invasive cancer testing solutions.

Expanding Testing Portfolio Recent launches of tests for head and neck cancer residual disease, along with ongoing development for multi-cancer early detection and minimal residual disease monitoring, open avenues for strategic partnerships with academic medical centers and oncology clinics.

Strong Funding & Recent Growth With a recent $48 million investment led by OrbiMed and revenue estimates between $100 million and $250 million, the company demonstrates robust financial backing and market traction, creating opportunities for joint ventures or co-marketing collaborations.

Scientific Leadership & Recognition Adela's CSO, Dr. Daniel De Carvalho, received the prestigious 2025 Canada Gairdner Momentum Award, highlighting the company's innovation and credibility, which can foster trust when approaching research institutions or government health agencies for partnerships.

Industry Collaborations Partnerships with organizations like Dendi and active participation in key industry events such as ASCO indicate a collaborative approach to product development and commercialization, making the company a strategic partner for oncology-focused distributors and service providers.